首页 | 本学科首页   官方微博 | 高级检索  
检索        

Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review
作者姓名:Ibrahim SM  Lewandowski RJ  Sato KT  Gates VL  Kulik L  Mulcahy MF  Ryu RK  Omary RA  Salem R
作者单位:Saad M Ibrahim(Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago 60611, United States) ; Robert J Lewandowski(Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago 60611, United States) ; Kent T Sato(Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago 60611, United States) ; Vanessa L Gates(Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago 60611, United States) ; Laura Kulik(Department of Medicine, Division of Hepatology, Northwestern Memorial Hospital, Chicago 60611, United States) ; Mary F Mulcahy(Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Chicago 60611, United States) ; Robert K Ryu(Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago 60611, United States) ; Reed A Omary(Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago 60611, United States) ; Riad Salem(Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Chicago 60611, United States) ;
摘    要:Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. The majority of patients with HCC present with unresectable disease. These patients have historically had limited treatment options secondary to HCC demonstrating chemoresistance to the currently available systemic therapies. Additionally, normal liver parenchyma has shown intolerance to tumoricidal radiation doses, limiting the use of external beam radiation. Because of these limitations, novel percutaneous liver-directed therapies have emerged. The targeted infusion of radioactive microspheres (radioembolization) represents one such therapy. Radioembolization is a minimally invasive transcatheter therapy through which radioactive microspheres are infused into the hepatic arteries that supply tumor. Once infused, these microspheres traverse the hepatic vascular plexus and selectively implant within the tumor arterioles. Embedded within the arterioles, the ^90y.impregnated microspheres emit high energy and low penetrating radiation doses selectively to the tumor. Radioembolization has recently shown promise for the treatment of patients with unresectable HCC. The objective of this review article is to highlight two currently available radioembolic devices ^90Y, ^188Rh) and provide the reader with a recent review of the literature.

关 键 词:肝细胞癌  短期治疗  钇-90  铼-188
收稿时间:2007 Dec 4

Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review
Ibrahim SM,Lewandowski RJ,Sato KT,Gates VL,Kulik L,Mulcahy MF,Ryu RK,Omary RA,Salem R.Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review[J].World Journal of Gastroenterology,2008,14(11):1664-1669.
Authors:Ibrahim Saad-M  Lewandowski Robert-J  Sato Kent-T  Gates Vanessa-L  Kulik Laura  Mulcahy Mary-F  Ryu Robert-K  Omary Reed-A  Salem Riad
Institution:1. Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago 60611, United States
2. Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago 60611, United States
3. Department of Medicine, Division of Hepatology, Northwestern Memorial Hospital, Chicago 60611, United States
4. Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Chicago 60611, United States
Abstract:Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. The majority of patients with HCC present with unresectable disease. These patients have historically had limited treatment options secondary to HCC demonstrating chemoresistance to the currently available systemic therapies. Additionally, normal liver parenchyma has shown intolerance to tumoricidal radiation doses, limiting the use of external beam radiation. Because of these limitations, novel percutaneous liver-directed therapies have emerged. The targeted infusion of radioactive microspheres (radioembolization) represents one such therapy. Radioembolization is a minimally invasive transcatheter therapy through which radioactive microspheres are infused into the hepatic arteries that supply tumor. Once infused, these microspheres traverse the hepatic vascular plexus and selectively implant within the tumor arterioles. Embedded within the arterioles, the 90Y impregnated microspheres emit high energy and low penetrating radiation doses selectively to the tumor. Radioembolization has recently shown promise for the treatment of patients with unresectable HCC. The objective of this review article is to highlight twocurrently available radioembolic devices (90Y, 188Rh) and provide the reader with a recent review of the literature.
Keywords:Radioembolization  Brachytherapy  Hepatocellular carcinoma  Yttrium-90  Rhenium-188
本文献已被 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号